| HAKL, Roman, Pavel KUKLÍNEK, Marta SOBOTKOVA, Irena KRCMOVA, Pavlina KRALICKOVA, Martina VACHOVA, Jana HANZLIKOVA, Martina NOVACKOVA, Michal SVOBODA, Ingrid KOVÁČOVÁ and Jiří LITZMAN. Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema. CLINICAL AND EXPERIMENTAL ALLERGY. HOBOKEN: WILEY, 2022, vol. 52, No 8, p. 994-997. ISSN 0954-7894. Available from: https://dx.doi.org/10.1111/cea.14182. |
Other formats:
BibTeX
LaTeX
RIS
@article{2215440,
author = {Hakl, Roman and Kuklínek, Pavel and Sobotkova, Marta and Krcmova, Irena and Kralickova, Pavlina and Vachova, Martina and Hanzlikova, Jana and Novackova, Martina and Svoboda, Michal and Kováčová, Ingrid and Litzman, Jiří},
article_location = {HOBOKEN},
article_number = {8},
doi = {http://dx.doi.org/10.1111/cea.14182},
keywords = {Icatibant; C1-inhibitor; hereditary angioedema; laryngeal attacks},
language = {eng},
issn = {0954-7894},
journal = {CLINICAL AND EXPERIMENTAL ALLERGY},
title = {Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema},
url = {https://onlinelibrary.wiley.com/doi/10.1111/cea.14182},
volume = {52},
year = {2022}
}
TY - JOUR
ID - 2215440
AU - Hakl, Roman - Kuklínek, Pavel - Sobotkova, Marta - Krcmova, Irena - Kralickova, Pavlina - Vachova, Martina - Hanzlikova, Jana - Novackova, Martina - Svoboda, Michal - Kováčová, Ingrid - Litzman, Jiří
PY - 2022
TI - Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema
JF - CLINICAL AND EXPERIMENTAL ALLERGY
VL - 52
IS - 8
SP - 994-997
EP - 994-997
PB - WILEY
SN - 09547894
KW - Icatibant
KW - C1-inhibitor
KW - hereditary angioedema
KW - laryngeal attacks
UR - https://onlinelibrary.wiley.com/doi/10.1111/cea.14182
N2 - Hereditary angioedema (HAE) is a rare condition which manifests as repeated episodes of localized subcutaneous or submucosal oedema. Oedemas involving the upper airways carry the risk of asphyxiation and death. The aim of this study was to present our clinical experience of icatibant and C1 inhibitor use for treating HAE-1/2 laryngeal attacks (LA). To our knowledge, this is the first direct comparison of these treatment approaches for LA.
ER -
HAKL, Roman, Pavel KUKLÍNEK, Marta SOBOTKOVA, Irena KRCMOVA, Pavlina KRALICKOVA, Martina VACHOVA, Jana HANZLIKOVA, Martina NOVACKOVA, Michal SVOBODA, Ingrid KOVÁČOVÁ and Jiří LITZMAN. Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema. \textit{CLINICAL AND EXPERIMENTAL ALLERGY}. HOBOKEN: WILEY, 2022, vol.~52, No~8, p.~994-997. ISSN~0954-7894. Available from: https://dx.doi.org/10.1111/cea.14182.
|
